Successful Treatment-Free Remission After Ponatinib Discontinuation in Pretreated Patients with Chronic Myeloid Leukemia in Chronic Phase

Fadi Haddad(The University of Texas MD Anderson Cancer Center), Hagop Kantarjian(The University of Texas MD Anderson Cancer Center), Koji Sasaki(The University of Texas MD Anderson Cancer Center), Ghayas C. Issa(The University of Texas MD Anderson Cancer Center), Jayastu Senapati(The University of Texas MD Anderson Cancer Center), Sara Dellasala(The University of Texas MD Anderson Cancer Center), Elias Jabbour(The University of Texas MD Anderson Cancer Center), Shimin Hu(The University of Texas MD Anderson Cancer Center)
Clinical Lymphoma Myeloma & Leukemia
November 6, 2024
10.1016/j.clml.2024.11.003
Cited by 4

Related Papers

Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
|New England Journal of Medicine|2002|2k
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|677
Ibrutinib and Venetoclax for First-Line Treatment of CLL
|New England Journal of Medicine|2019|502
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia
|Nature|2023|450
Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia
|Blood|2010|399